Journals / Journal of the Turkish-German Gynecological Association / 2019 / Cilt: 20 - Sayı: 4

Uncommon borderline ovarian tumours: A clinicopathologic study of seventeen patients

Pages
224–230
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, endometrialpathology should be checked in endometrioid type

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To evaluate uncommon types of borderline ovarian tumors (BOT) and define the clinical, surgical, and pathologic features.Material and Methods: Seventeen patients who were treated in our hospital between 1990 and 2017 were identified.
📊
Key Findings & Data:Conservative surgery was defined aspreservation of the uterus and at least part of one ovary.Results: The mean age was 47 (range, 22-70) years.
💡
Conclusion & Impact:However, endometrialpathology should be checked in endometrioid type
🔬Design:Research Article
📍Scope:2017 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: To evaluate uncommon types of borderline ovarian tumors (BOT) and define the clinical, surgical, and pathologic features.Material and Methods: Seventeen patients who were treated in our hospital between 1990 and 2017 were identified. Patients’ data werecollected from the gynecologic oncology clinic electronic database, patients’ files, and pathology reports. Conservative surgery was defined aspreservation of the uterus and at least part of one ovary.Results: The mean age was 47 (range, 22-70) years. Based on histopathologic tumor type, there was mixed tumor in five (29.4%) patients,endometrioid-type in nine (52.9%), seromusinous-type in two (11.8%), and Brenner-type in one (5.9%). Conservative surgery was performed in4 patients. Two patients with endometrioid BOT had synchronous endometrial pathology, including one (11%) patient with endometrial cancer,one (11%) with endometrial hyperplasia without atypia, and 3 (33%) patients had endometriosis. The median follow-up was 19 (range, 1-137)months. No recurrence was observed during the follow-up period.Conclusion: In our small volume case series, it could be said that non-serous/non-mucinous BOT has excellent prognosis. However, endometrialpathology should be checked in endometrioid type

🔖

Cite This Article

TURAN, T., ÇAKIR, C., YÜKSEL, D., KILIÇ, Ç., BOYRAZ, G., KARALÖK, A., DURMUŞ, Y., BORAN, N., CÖMERT, G. K. (2022). Uncommon borderline ovarian tumours: A clinicopathologic study of seventeen patients. Journal of the Turkish-German Gynecological Association, Cilt: 20 - Sayı: 4, 224–230. https://ajindex.com/articles/567463

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Suh-Burgmann E. Long-term outcomes following conservative surgery for borderline tumor of the ovary: A large population-based study. Gynecol Oncol 2006; 103: 841-7
  2. Hauptmann S, Friedrich K, Redline R, Avril S. Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria. Virchows Arch 2017; 470: 125-42
  3. Taylor HC, Malignant and semi-malignant tumours of the ovary. Surg Gynecol Obstet 1929; 48: 204-30
  4. No authors listed. Classification and staging of malignant tumours in the female pelvis. Acta Obstet Gynecol Scand 1971; 50: 1-7
  5. Kurman RJ, Carcangiu ML, Herrington CS, Young RHE. WHO classification of tumours of female reproductive organs. IARC: Lyon; 2014
  6. Seidman JD, Soslow RA, Vang R, Berman JJ, Stoler MH, Sherman ME, et al. Borderline ovarian tumors: diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images. Hum Pathol 2004; 35: 918-33
  7. Fischerova D, Zikan M, Dundr P, Cibula D. Diagnosis, Treatment, and Follow-Up of Borderline Ovarian Tumors. Oncologist 2012; 17: 1515-33
  8. Ayhan A, Guvendag Guven ES, Guven S, Kucukali T. Recurrence and prognostic factors in borderline ovarian tumors. Gynecol Oncol 2005; 98: 439-45
  9. Scully RE, Young RH, Clement PB. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. Atlas of Tumor Pathology. 3rd Series, Fascicle 23. Washington, DC: Armed Forces Institute of Pathology 1998; 1-168
  10. Fauvet R, Poncelet C, Booccara J, Descamps P, Fondrinier E, Darai E. Fertility after conservative treatment for borderline ovarian tumours: a French multicenter study. Fertil Steril 2005; 83: 284-90
  11. Morice P, Camatte S, El Hassan J, Pautier P, Duvillard P, Castaigne D. Clinical outcomes and fertility after conservative treatment of ovarian borderline tumours. Fertil Steril 2001; 75: 92-6. 12. du Bois A, Ewald-Riegler N, du Bois O, Harter P. Borderline tumours of the ovary: a systematic review. Geburtshilfe Frauenheilkd 2009; 69: 807-33
  12. Nayyar N, Lakhwani P, Goel A, Pande PK, Kumar K. Management of Borderline Ovarian Tumors-Still a Gray Zone. Indian J Surg Oncol 2017; 8: 607-14
  13. Tempfer CB, Polterauer S, Bentz EK, Reinthaller A, Hefler LA. Accuracy of intraoperative frozen section analysis in borderline tumours of the ovary: a retrospective analysis of 96 cases and review of the literature. Gynecol Oncol 2007; 107: 248-52
  14. Ureyen I, Turan T, Cirik DA, Tasci T, Boran N, Bulbul D, et al. Frozen sect